Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 23;13:1068855. doi: 10.3389/fphar.2022.1068855

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zhang, Liu, Liu and Xiao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Wogonin combined with gemcitabine inhibits the proliferation of pancreatic cancer cells. (A) The cell viability of Panc-1 and Bxpc-3 cells treated with gemcitabine was assessed using MTT assay at 72 h. Compared with Bxpc-3, Gemcitabine displayed no significant antiproliferative effects to Panc-1 cell. (B) The cell viability of Panc-1 treated with wogonin was assessed using MTT assay at 72 h. The cell viability decreased with the elevated concentration of wogonin. (C) Sensitizing effect of wogonin in Panc-1 cells to gemcitabine. Cells were treated with gemcitabine (0, 0.04, 0.08, 0.15, 0.3, 0.6, 1.3, 2.5, 5 and 10 μM), Gem + Wog (10 μM) and Gem + Wog (20 μM) for 72 h and cell viability was determined by MTT assay. *p < 0.05, **p < 0.01, ***p < 0.001 vs. controls.